Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipoprotein (a): implication in atherothrombosis

M J Chapman1, T Huby, F Nigon

  • 1INSERM Unité 321, Unité de Recherche sur les Lipoprotéines et l'Athérogénèse, Hôpital de la Pitié, Paris, France.

Atherosclerosis
|October 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondrial STAT3-mediated suppression of apoptosis constrains antimycobacterial immunity.

bioRxiv : the preprint server for biology·2026
Same author

HnRNPA2B1 tunes antimycobacterial immune responses in macrophages through alternative splicing of <i>Irgm1</i>.

Infection and immunity·2026
Same author

HnRNPA2B1 tunes antimycobacterial immune responses in macrophages through alternative splicing of <i>Irgm1</i>.

bioRxiv : the preprint server for biology·2025
Same author

Modulation of Gr1<sup>low</sup> monocyte subset impacts insulin sensitivity and weight gain upon high-fat diet in female mice.

International journal of obesity (2005)·2017
Same author

The rapid and accurate categorisation of critically ill patients (RACE) to identify outcomes of interest for longitudinal studies: a feasibility study.

Anaesthesia and intensive care·2017
Same author

Occult upper gastrointestinal mucosal abnormalities in critically ill patients.

Acta anaesthesiologica Scandinavica·2016

Lipoprotein (a) is a risk factor for cardiovascular disease. Small lipoprotein (a) isoforms (< or = 500 kDa) inhibit fibrinolysis and bind to fibrin, increasing atherothrombotic risk.

Area of Science:

  • Cardiovascular Science
  • Biochemistry
  • Thrombosis Research

Background:

  • Lipoprotein (a) [Lp(a)] is an established independent risk factor for premature cardiovascular disease.
  • Elevated plasma Lp(a) levels and specific apo(a) phenotypes predict ischemic heart disease risk.
  • Lp(a) accumulation in vascular tissue and atherosclerotic plaques contributes to cardiovascular risk.

Purpose of the Study:

  • To investigate the differential effects of Lp(a) isoforms on fibrinolysis and fibrin binding.
  • To elucidate the mechanisms underlying Lp(a)-associated atherothrombotic risk.

Main Methods:

  • In vitro studies using purified Lp(a) isoforms.
  • Assays to measure inhibition of plasminogen activation.
  • Fibrin binding affinity studies.

Related Experiment Videos

Main Results:

  • Small Lp(a) isoforms (< or = 500 kDa) efficiently inhibit plasminogen activation.
  • Small Lp(a) isoforms exhibit high affinity binding to fibrin.
  • Large Lp(a) isoforms (> 500 kDa) show minimal inhibitory effects on fibrinolysis.

Conclusions:

  • Small Lp(a) isoforms are potent inhibitors of fibrinolysis.
  • High-affinity binding of small Lp(a) isoforms to fibrin contributes significantly to atherothrombotic risk.
  • Isoform size is a critical determinant of Lp(a)'s prothrombotic and atherogenic potential.